Publication of this issue is partly supported via a contribution by Celgene
TABLE OF CONTENTS
Volume 23, Issue 11 (November 2009)
Editorial
Commentary on Perrone et al.: 'Vitamin C: not for breakfast anymore...if you have myeloma'
R D Harvey, J Nettles, B Wang, S-Y Sun and S Lonial
Leukemia 23: 1939-1940; doi:10.1038/leu.2009.128
Spotlight Reviews
The molecular characterization and clinical management of multiple myeloma in the post-genome era FREE
Y Zhou, B Barlogie and J D Shaughnessy Jr
Leukemia 23: 1941-1956; advance online publication, August 6, 2009; doi:10.1038/leu.2009.160
Harmonization of molecular monitoring of CML therapy in Europe FREE
M C Müller, N C P Cross, P Erben, T Schenk, B Hanfstein, T Ernst, R Hehlmann, S Branford, G Saglio and A Hochhaus
Leukemia 23: 1957-1963; advance online publication, August 27, 2009; doi:10.1038/leu.2009.168
Proteasome inhibitors in the treatment of multiple myeloma
J J Shah and R Z Orlowski
Leukemia 23: 1964-1979; advance online publication, September 10, 2009; doi:10.1038/leu.2009.173
Review
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
A Österborg, R Foà, R F Bezares, C Dearden, M J S Dyer, C Geisler, T S Lin, M Montillo, M H J van Oers, C-M Wendtner and K R Rai
Leukemia 23: 1980-1988; advance online publication, July 23, 2009; doi:10.1038/leu.2009.146
Original Articles
Acute Leukemias
PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study
J Familiades, M Bousquet, M Lafage-Pochitaloff, M-C Béné, K Beldjord, J De Vos, N Dastugue, E Coyaud, S Struski, C Quelen, N Prade-Houdellier, S Dobbelstein, J-M Cayuela, J Soulier, N Grardel, C Preudhomme, H Cavé, O Blanchet, V Lhéritier, A Delannoy, Y Chalandon, N Ifrah, A Pigneux, P Brousset, E A Macintyre, F Huguet, H Dombret, C Broccardo and É Delabesse
Leukemia 23: 1989-1998; advance online publication, July 9, 2009; doi:10.1038/leu.2009.135
Chronic Myeloproliferative Neoplasias
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
A Davies, N E Jordanides, A Giannoudis, C M Lucas, S Hatziieremia, R J Harris, H G Jørgensen, T L Holyoake, M Pirmohamed, R E Clark and J C Mountford
Leukemia 23: 1999-2006; advance online publication, August 27, 2009; doi:10.1038/leu.2009.166
Chronic Lymphocytic Leukemia
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
S Böttcher, S Stilgenbauer, R Busch, M Brüggemann, T Raff, C Pott, K Fischer, G Fingerle-Rowson, H Döhner, M Hallek, M Kneba and M Ritgen on behalf of the German CLL study group
Leukemia 23: 2007-2017; advance online publication, July 30, 2009; doi:10.1038/leu.2009.140
Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia
A Farfsing, F Engel, M Seiffert, E Hartmann, G Ott, A Rosenwald, S Stilgenbauer, H Döhner, M Boutros, P Lichter and A Pscherer
Leukemia 23: 2018-2026; advance online publication, July 30, 2009; doi:10.1038/leu.2009.144
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
A Cortelezzi, M C Pasquini, A Gardellini, U Gianelli, A Bossi, G Reda, B Sarina, P Musto, W Barcellini, A Neri and G L Deliliers
Leukemia 23: 2027-2033; advance online publication, July 30, 2009; doi:10.1038/leu.2009.148
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
K D Mason, S L Khaw, K C Rayeroux, E Chew, E F Lee, W D Fairlie, A P Grigg, J F Seymour, J Szer, D C S Huang and A W Roberts
Leukemia 23: 2034-2041; advance online publication, July 30, 2009; doi:10.1038/leu.2009.151
Stem Cells
Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4+ very small embryonic-like stem cells FREE
D M Shin, E K Zuba-Surma, W Wu, J Ratajczak, M Wysoczynski, M Z Ratajczak and M Kucia
Leukemia 23: 2042-2051; advance online publication, July 30, 2009; doi:10.1038/leu.2009.153
Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes
H M Lee, W Wu, M Wysoczynski, R Liu, E K Zuba-Surma, M Kucia, J Ratajczak and M Z Ratajczak
Leukemia 23: 2052-2062; advance online publication, August 6, 2009; doi:10.1038/leu.2009.158
Normal Hemopoiesis
The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate
K De Luca, V Frances-Duvert, M-J Asensio, R Ihsani, E Debien, M Taillardet, E Verhoeyen, C Bella, S Lantheaume, L Genestier and T Defrance
Leukemia 23: 2063-2074; advance online publication, July 30, 2009; doi:10.1038/leu.2009.155
Immunology
Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population
N Weston-Bell, M Townsend, G Di Genova, F Forconi and S S Sahota
Leukemia 23: 2075-2080; advance online publication, September 24, 2009; doi:10.1038/leu.2009.178
Oncogenes, Fusion Genes and Tumor Suppressor Genes
Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1
J-M Terme, V Mocquet, A-S Kuhlmann, L Zane, F Mortreux, E Wattel, M Duc Dodon and P Jalinot
Leukemia 23: 2081-2089; advance online publication, July 9, 2009; doi:10.1038/leu.2009.131
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells
H Hasegawa, Y Yamada, H Iha, K Tsukasaki, K Nagai, S Atogami, K Sugahara, K Tsuruda, A Ishizaki and S Kamihira
Leukemia 23: 2090-2101; advance online publication, August 27, 2009; doi:10.1038/leu.2009.171
Transcriptional Control and Signal Transduction
IL-6, but not IFN-
, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing
G Regis, L Icardi, L Conti, R Chiarle, R Piva, M Giovarelli, V Poli and F Novelli
Leukemia 23: 2102-2108; advance online publication, July 23, 2009; doi:10.1038/leu.2009.139
Animal Models
A robust xenotransplantation model for acute myeloid leukemia
P V Sanchez, R L Perry, J E Sarry, A E Perl, K Murphy, C R Swider, A Bagg, J K Choi, J A Biegel, G Danet-Desnoyers and M Carroll
Leukemia 23: 2109-2117; advance online publication, July 23, 2009; doi:10.1038/leu.2009.143
Lymphoma
Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
M Plander, S Seegers, P Ugocsai, S Diermeier-Daucher, J Iványi, G Schmitz, F Hofstädter, S Schwarz, E Orsó, R Knüchel and G Brockhoff
Leukemia 23: 2118-2128; advance online publication, August 6, 2009; doi:10.1038/leu.2009.145
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma
S Eckerle, V Brune, C Döring, E Tiacci, V Bohle, C Sundström, R Kodet, M Paulli, B Falini, W Klapper, A B Chaubert, K Willenbrock, D Metzler, A Bräuninger, R Küppers and M-L Hansmann
Leukemia 23: 2129-2138; advance online publication, August 6, 2009; doi:10.1038/leu.2009.161
Myeloma
Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
S Colucci, G Brunetti, G Mori, A Oranger, M Centonze, C Mori, F P Cantatore, R Tamma, R Rizzi, V Liso, A Zallone and M Grano
Leukemia 23: 2139-2146; advance online publication, July 9, 2009; doi:10.1038/leu.2009.136
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M A Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, E A Stadtmauer, M T Petrucci, Z Yu, M Olesnyckyj, J B Zeldis, R D Knight and D M Weber
Leukemia 23: 2147-2152; advance online publication, July 23, 2009; doi:10.1038/leu.2009.147
Letters to the Editor
Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)
I Nagel, S Bug, H Tönnies, O Ammerpohl, J Richter, I Vater, E Callet-Bauchu, M J Calasanz, J A Martinez-Climent, C Bastard, M Salido, E Schroers, J I Martin-Subero, S Gesk, L Harder, A Majid, M J S Dyer and R Siebert
Leukemia 23: 2153-2155; advance online publication, August 20, 2009; doi:10.1038/leu.2009.149
Imatinib mesylate causes growth plate closure in vivo
K Vandyke, A L Dewar, S Fitter, D Menicanin, L B To, T P Hughes and A C W Zannettino
Leukemia 23: 2155-2159; advance online publication, July 23, 2009; doi:10.1038/leu.2009.150
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia
R Bhat, S Malinge, A S Gamis, A D Sorrell, J M Hilden, R P Ketterling, E Paietta, M S Tallman and J D Crispino
Leukemia 23: 2159-2160; advance online publication, August 6, 2009; doi:10.1038/leu.2009.159
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures
I Del Giudice, N Osuji, T Dexter, V Brito-Babapulle, N Parry-Jones, S Chiaretti, M Messina, G Morgan, D Catovsky and E Matutes
Leukemia 23: 2160-2167; advance online publication, July 30, 2009; doi:10.1038/leu.2009.137
Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis
K Eberhart, K Renner, I Ritter, M Kastenberger, K Singer, C Hellerbrand, M Kreutz, R Kofler and P J Oefner
Leukemia 23: 2167-2170; advance online publication, August 6, 2009; doi:10.1038/leu.2009.154
Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D3
C Nishioka, T Ikezoe, J Yang and A Yokoyama
Leukemia 23: 2171-2173; advance online publication, August 6, 2009; doi:10.1038/leu.2009.152
miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia?
B Cardinaud, C Moreilhon, B Marcet, K Robbe-Sermesant, K LeBrigand, B Mari, V Eclache, F Cymbalista, S Raynaud and P Barbry
Leukemia 23: 2174-2177; advance online publication, June 18, 2009; doi:10.1038/leu.2009.125
Increased expression of macrophage inflammatory protein-1
on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
M Roussou, A Tasidou, M A Dimopoulos, E Kastritis, M Migkou, D Christoulas, M Gavriatopoulou, F Zagouri, C Matsouka, D Anagnostou and E Terpos
Leukemia 23: 2177-2181; advance online publication, July 9, 2009; doi:10.1038/leu.2009.130
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
D Gutman, A A Morales and L H Boise
Leukemia 23: 2181-2183; advance online publication, June 11, 2009; doi:10.1038/leu.2009.123
Mutations of ASXL1 gene in myeloproliferative neoplasms
N Carbuccia, A Murati, V Trouplin, M Brecqueville, J Adélaïde, J Rey, W Vainchenker, O A Bernard, M Chaffanet, N Vey, D Birnbaum and M J Mozziconacci
Leukemia 23: 2183-2186; advance online publication, July 16, 2009; doi:10.1038/leu.2009.141
Corrigendum
HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation FREE
H Akl, B M Badran, N El Zein, F Bex, C Sotiriou, K E Willard-Gallo, A Burny and P Martiat
Leukemia 23: 2187; doi:10.1038/leu.2009.201
